LENZ Therapeutics (LENZ) Operating Margin (2025 - 2026)

LENZ Therapeutics' (LENZ) quarterly Operating Margin came in at 2321.67% in Q1 2026, down 854.51% on a QoQ basis from 307.7% in Q4 2025.

LENZ Therapeutics (LENZ) Operating Margin (2025 - 2026) Analysis & Trends

LENZ Therapeutics (LENZ) has 2 years of Operating Margin data on file, last reported at 2321.67% in Q1 2026.

On a quarterly basis, Operating Margin changed N/A year-over-year to 2321.67% in Q1 2026; TTM through Mar 2026 was 1714.85%, a N/A change from a year earlier, with the FY2025 full-year figure at 1822.76%, changed N/A from the prior year.
Operating Margin for Q1 2026 stood at 2321.67%, down from 307.7% in the prior quarter.
Over the last five years, Operating Margin for LENZ reached as high as 307.7% in Q4 2025 and fell as low as 2321.67% in Q1 2026.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Operating Margin (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	16.51%
4	NuCana	279.75 Bn	279.75 Bn	-	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	38.10%
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	17.83%
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	31.68%
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	-
10	LENZ Therapeutics	158.34 Mn	158.34 Mn	825,000.00	-2,321.67%

Download Data